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Abstract
Intravesical administration of Bacillus Calmette-Guérin is used as a treatment method in superficial
bladder cancer. While it is generally well tolerated, serious side effects may develop.
Granulomatous hepatitis cases have been previously reported; however, only one case with
tuberculous peritonitis exists in the current literature. We hereby present two cases, one of which
is the second tubercular peritonitis case following Bacillus Calmette-Guérin treatment to be
reported, and the other a case with granulomatous hepatitis. Complete cure was achieved in both
cases with specific therapy. In the patient who developed peritonitis, intravesical Bacillus Calmette-
Guérin therapy was recommenced after antituberculosis treatment, and completed without further
complications.
Introduction
Bacillus Calmette-Guérin (BCG) was introduced to intra-
vesical use in high-risk superficial bladder cancer by
Morales  et al. in 1976 [1]. While the pathogenesis is
unclear, it is thought to elicit a local inflammatory
response [2]. Local side effects due to BCG administration
are frequent (90%), and may include hematuria, and dys-
uria along with cystitis [3]. Various other local and sys-
temic side effects such as acute respiratory failure and
septic shock [4], hemolytic uremic syndrome, dissemi-
nated intravascular coagulation, sepsis, multi-organ fail-
ure [5,6], isolated renal tuberculosis (TB) [7],
granulomatous hepatitis [8,9], peritonitis [10], pancyto-
penia, epididymo-orchitis [11], and diffuse granuloma-
tous mesenteric disease [12] have also been reported. Steg
et al. described a 3% and Lamm et al. around 0.7% inci-
dence of BCG-related granulomatous hepatitis [3,13].
There exist case reports of TB peritonitis following BCG
vaccination in children [14] and only one case report of
peritoneal TB following the administration of BCG treat-
ment for bladder cancer [10]. To the best of our knowl-
edge, our patient with peritoneal TB related to intravesical
BCG treatment is the second case reported so far, and for
the first time initially planned BCG therapy following spe-
cific treatment of this complication was completed.
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Case report 1
A 35-years-old female patient of bladder cancer was
admitted to the hospital for the second intravesical BCG
administration 15 days after the first dose. She had had
sudden-onset abdominal distention and pain for the last
two days. The second dose of BCG to had already been
postponed for a week previously due to presence of hema-
turia. The hematuria was considered to be secondary to
the tumor since there was no biopsy or surgical interven-
tion history in the last 30 days as well as no finding of an
infection. Transurethral bladder tumor resection and
biopsy were performed 1 month before. Medical history
did not reveal previous TB, liver disease, or drug use. The
only finding upon physical examination was extensive
ascites. Laboratory tests showed aspartate aminotrans-
ferase (AST) 49 U/L (normal range (N): 5–34), alanine
aminotransferase (ALT) 57 IU/L (N: 0–55), GGT: 105 (N:
9–64) IU/L, sedimentation 42 mm/h, CRP: 12 mg/dL (N:
0–5), and CA-125: 625 IU/ml (N: <35). Viral markers and
autoantibodies were negative. Examination of the ascites
fluid showed predominantly lymphocytes (85% lym-
phocyte, 15% PMNL) and benign mesothelial cells, with
an absence of atypical cells. Glucose content was 88 mg/
dl, total protein was 5.3 g/dl and albumin was 2.4 g/dl.
Bacteria or acid-resistant bacilli were absent in microbio-
logical investigation; culture and PCR assessments were
negative. Adenosine deaminase (ADA) was 180 IU/L (N:
0–40). There was no pathology in the abdominal ultra-
sonography aside from the liver being at the upper limit
of physiologically normal dimensions. Presence of BCG
treatment history, >80% lymphocyte in ascites fluid,
ADA> 70 IU/L and high CA-125 levels and exclusion of
other possible conditions for differential diagnosis by fur-
ther examinations led us to begin anti-TB treatment with-
out delay due to the lack of any other explanation for the
findings.
The patient was placed under treatment with three-agent
therapy (isoniazid, rifampin, ethambutol) for two
months and dual-agent therapy for seven months. Totally
the anti-TB treatment was maintained for 9 months. AST,
ALT, GGT returned to normal levels; CA-125 was 161 U/ml
on day 15. At month three, physical examination findings
and all laboratory parameters were within normal limits.
Ten months after the discontinuation of therapy, BCG
administration was completed to 6 doses, and there was
no pathology at follow-up 2 years later.
Case report 2
This 46-year old male patient presented with complaints
of fatigue, fever and nausea following the fifth dose of
intravesical BCG administration. Medical history revealed
no liver disease or drug use. Pathological physical exami-
nation findings were fever (38.4°C), hypotension (85/60
mmHg), and hepatomegaly (4 cm). Laboratory tests
revealed CRP: 20 mg/dL, sedimentation: 79 mm/h, AST:
137 U/L, ALT: 121 IU/L, GGT: 245 IU/L. Autoantibodies,
viral markers, hemogram, and other parameters were nor-
mal. Blood culture, urine culture and PCR were negative.
Liver biopsy histology showed noncaseating granuloma-
tous hepatitis with Langhans giant cells; acid-fast bacilli
stain was negative (Figure 1 and figure 2). The patient was
placed under treatment with isoniazid and rifampin. On
the 15th day of treatment, AST was 52 U/L, ALT: 61 IU/L,
GGT: 108 IU/L. On the 20th day of therapy, ethambutol
was added due to reemergence of fever and an increase in
liver enzyme levels. 10 days after the initiation of three-
agent therapy, 60 mg/day methylprednisolone was added
due to the lack of improvement in clinical and laboratory
findings. On the fourth day of corticosteroid therapy, clin-
ical improvement and a decline in liver enzymes were
observed. Steroid treatment was discontinued by gradu-
ally tapering after 1.5 months. In the third month of treat-
ment, AST was 35 U/L, and ALT 32 IU/L. Treatment was
discontinued by the sixth month of treatment. Control
values one month after discontinuation were normal.
Discussion
BCG is considered to exert an anti-tumor effect via a T-cell
mediated immune response [15]. The immune system
stimulation by BCG results in the detection of T-lym-
phocyte infiltration in the lamina propria for at least 3
months. This infiltration leads to an increase in cytotoxic
T-cells and macrophages. Thus, severe local inflammation
causes local ischemia and the destruction of tumor cells
[16,17]. Intravesical BCG administration causes common
local side effects such as hematuria, cystitis, bladder con-
tracture, granulomatous prostatitis, and renal abscess.
Granuloma and lymphocytic infiltration overlapping the limit- ing membrane in the portal region Figure 1
Granuloma and lymphocytic infiltration overlapping 
the limiting membrane in the portal region. Steatosis 
and granulomas in the liver parenchyma. (H&E×100).Annals of Clinical Microbiology and Antimicrobials 2009, 8:12 http://www.ann-clinmicrob.com/content/8/1/12
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These are related to the inflammatory response to BCG or
the contamination of the urinary system with BCG [18].
Systemic side effects are more infrequent. Factors that
increase the risk of systemic side effects include bladder
biopsy during BCG treatment, transurethral resection of
prostate or bladder tumors, traumatic catheterization, and
simultaneous cystitis [19]. Use of immunosuppressive
agents, diseases such as diabetes, and genetic factors are
also important risk factors [20].
The clinical symptoms of an ordinary TB peritonitis com-
prise 95% abdominal pain, 92% ascites and 82% abdom-
inal distention, and culture tests are usually negative.
Only three of 39 cases with TB peritonitis in the absence
of BCG administration were culture-positive [21]. The cul-
ture, TB-PCR of ascites fluid and direct examination were
negative in our case too. The patient was not subjected to
biopsy, transurethral resection or any other invasive pro-
cedure in the last 30 days and did not have cystitis that
would lead to ascites. Thus anti-TB treatment was initiated
since ascites developed 15 days after the first dose of BCG
and lack of any interventional procedure. Development of
TB peritonitis due to BCG treatment is rarely reported
[10,22]. In previously reported TB peritonitis case, ascites
developed 3 months after the first dose of BCG and fever
accompanied ascites development. However, in that case
the patient was under peritoneal dialysis and peritoneal
dialysis might well have delayed the development of
ascites and the diagnosis [22]. The fluid chemistry-high
ascitic ADA, ascitic fluid/serum ADA ratio and serum CA-
125 level – was also consistent with TB peritonitis. The
ascitic fluid/serum ADA ratio is higher in patients with
peritoneal TB than with other causes of ascites. The opti-
mal cut-off value for ADA was suggested to be 39 IU/L and
that its sensitivity (97%) and specifity (100%) were very
high in previous studies [23,24]. Serum CA-125 levels in
patients with TB peritonitis are as high as ovarian cancers
associated with peritoneal infiltration. Serum CA-125 lev-
els fall between normal ranges after treatment and consid-
ered as a useful marker in the diagnosis and follow-up of
patients with TB peritonitis [25,26]. The diagnosis of TB
peritonitis is still difficult because of unstable presenta-
tion, low percentage of positive microscopy for acid-fast
bacilli and the time delay of up to several weeks for a pos-
itive TB culture [27]. TB peritonitis may be fatal but is
medically cured if diagnosed in a timely fashion.
Although both non-invasive and invasive tests have addi-
tional benefits, clinical suspicion is still the first step for
the diagnosis of TB peritonitis [28] and therefore empiri-
cal anti-TB treatment is indicated to patients with fluid
analysis consistent with TB peritonitis if other possible
causes are ruled out [29]. In the absence of a definitive
treatment protocol for post-BCG TB peritonitis, we
administered isoniazid, rifampin and ethambutol in the
first 2 months, followed by a two-agent maintenance ther-
apy for 7 months. Intravesical BCG treatment was rein-
stated nine months after treatment discontinuation, and
completed to 6 doses. Certain publications do not recom-
mend the reinstatement of BCG therapy in patients who
develop systemic BCG infections [30]. In our patient, the
reiteration of therapy did not cause any new pathology.
Successful cure was achieved with local BCG treatment.
This experience indicates that BCG treatment may be
recommenced if the infection that develops after BCG
administration is not considered a hypersensitivity reac-
tion. However, continuation of intravesical BCG therapy
is not recommended in cases that develop granulomatous
hepatitis due to the potential of hypersensitivity reactions.
The incidence of BCG-related granulomatous hepatitis
was 0.7% in a large series consisting of 2602 patients [3].
A later study by Steg et al. reported the incidence of serious
side effects as 3%. Asymptomatic granulomas may emerge
4 to 40 months after BCG administration, while sympto-
matic hepatitis becomes apparent in the first few months.
In the study by Steg et al., four cases with BCG-related hep-
atitis were detected after several administrations, but one
case was discovered 6 months after the completion of a
two-year maintenance therapy [13]. Liver biopsy reveals
granulomas in all hepatitis cases, and a direct smear for
mycobacteria plays an important role. In one patient,
blood culture was positive for mycobacteria after the first
administration [30]. Leebeek et al. detected mycobacterial
DNA in the liver tissue of a case with granulomatous hep-
atitis for the first time [31]. However, the detection of
acid-fast bacilli in liver, blood, and bone marrow speci-
mens is quite difficult. Even though acid-fast bacilli are
Granulomas composed of Langhans giant cell, epithelioid his- tiocytosis and eosinophils in the parenchyma Figure 2
Granulomas composed of Langhans giant cell, epi-
thelioid histiocytosis and eosinophils in the paren-
chyma. (H&E×200).Annals of Clinical Microbiology and Antimicrobials 2009, 8:12 http://www.ann-clinmicrob.com/content/8/1/12
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positive in 10% of all liver tuberculosis cases, DNA
hybridization studies are often negative [32]. Similar to
most other cases, urine culture, blood culture, and PCR
were negative in the reported cases [9,30,33].
The development of BCG-related granulomatous hepatitis
is alleged to be a hypersensitivity reaction to the protein
fraction of BCG [34]. Granulomatous hepatitis cases that
are not responsive to anti-TB drugs and corticosteroids
exist [33,35]. The treatment of these cases always involves
steroids together with anti-tuberculosis therapy [34].
Hypersensitivity and infection cannot be differentiated
histopathologically and clinically; anti-TB agents and ster-
oids can be co-administered until culture tests are final-
ized [30,31,33,35]. No definitive treatment regimen has
been established for BCG-related granulomatous hepati-
tis, but early treatment is recommended [3,30,32]. The
recommended first-line therapy for granulomatous hepa-
titis is isoniazid plus rifampin. Clinical progress is moni-
tored by the decline and normalization of liver function
tests. If signs of a hypersensitivity reaction are present,
steroids are added [30]. The addition of prednisolone to
the treatment protocol in patients with elevated liver func-
tion tests despite a 6-month therapy with rifampin and
isoniazid resulted in an improvement in laboratory and
histological tests. Rapid response to therapy is a clinical
sign that supports hypersensitivity [33]. The recom-
mended therapy for severe systemic BCG infection is the
administration of isoniazid, rifampin and ethambutol for
six months [3,13,32]. Treatment with pyrazinamide is not
recommended, as all forms of M. bovis are resistant [30].
While some investigators recommend prophylactic ther-
apy with 300 mg isoniazid daily, others suggested that this
might diminish the anti-tumor effect of BCG [3]. On the
other hand a more recent study failed to find any evidence
of either benefit or harm in giving prophylactive INH and
prophylactive ofloxacin was beneficial in reducing moder-
ate-severe side effects [36,37].
Even in the absence of traumatic administration, patients
should be monitored for side effects during BCG treat-
ment. Liver function tests must be monitored during BCG
treatment. BCG-related granulomatous hepatitis should
be considered in cases of abnormal liver function tests and
persistent fever following BCG therapy. In cases with an
appropriate clinical presentation, negative culture tests
should not be a cause for treatment delay. It should be
remembered that early treatment improves the chance of
success.
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